Receptor

Labroots Announces its 8th Annual Laboratory Automation Virtual Event, Scheduled on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Automaton, Automation, Receptor, Almost, Q&A, Cell, Protein, Laboratory automation, MIT, LIMS, Sartorius, CDS, Research, Science News, WEI, Media lab, Science, Doctor of Philosophy, Networking hardware, Laboratory, Cytokine, CRISPR, Immortalised cell line, Labroots, Molecular biology, Medicine, UCLA, Antigen

YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024. This free event brings together thousands of research scholars, scientists, and laboratory personnel from leading academic and industry institutions under a virtual roof to explore scientific disciplines with sessions spanning microfluidic and microscale technologies for automation, automation and emerging methods, lab automation with cutting-edge tools, LIMS and other automation software, and analytics for high-throughput and high content assays.

Key Points: 
  • YORBA LINDA, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 8th annual Laboratory Automation online event on March 20, 2024.
  • The insightful agenda encompasses leading-edge advancements aimed at automating and accelerating research, and amplifying efficiency in the lab.
  • A lively Q&A session, following the presentation sponsored by Automata titled, "How to Prepare for Lab Automation."
  • Participants can use the official hashtag #LRlabauto to follow the conversation and connect with other members in the Laboratory Automation community!

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

Retrieved on: 
Wednesday, September 6, 2023
Real-World Evidence, Seizure, ASA, Abstract (summary), Abstract, Cleveland Clinic, Central nervous system, Doctor of Pharmacy, Trevena Inc, Use, Senior, Delirium, Vomiting, TMS, Trevena, American Society of Anesthesiologists, Spasm, Research, CNS, Sale, Conference call, Patient, Webcast, Pain, Society, Conference, Receptor, Rare-earth element, Cryptocurrency, Pharmaceutical industry

This tranche of funding was triggered by the first commercial sale of OLINVYK in China by Jiangsu Nhwa, the Company’s licensee in China.

Key Points: 
  • This tranche of funding was triggered by the first commercial sale of OLINVYK in China by Jiangsu Nhwa, the Company’s licensee in China.
  • The $15 million tranche is in addition to the $28.1 million of cash and cash equivalents the Company previously reported as of June 30, 2023.
  • As part of the R-Bridge Financing, Trevena may receive an additional $10 million upon achievement of either a commercial or financing milestone.
  • Trevena expects to report new respiratory data from the study using continuous respiratory monitoring in 3Q 2023.

Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies

Retrieved on: 
Thursday, April 13, 2023
Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Other Science, Science, Oncology, DNA, Methylation, Twist Bioscience, Doctor of Philosophy, Martek Biosciences Corporation, Toxicity, RNA, TCR, CAR, Engineering, Twist, Silicon, Library, Receptor, Vaccine, Pharmaceutical industry, Serotiny

These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.

Key Points: 
  • These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.
  • “With the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “Twist CAR and TCR Libraries allow researchers and drug developers to fine tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic.”
    Twist TCR and CAR Libraries are large and diverse libraries made of up to 10,000 gene fragment combinations.
  • Information about the Twist TCR and CAR Libraries will be available at the Twist booth at the AACR Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Breast, Blood, Administration, EGFR, TCR, Telephone, Biotechnology, Poster, Toxic shock syndrome toxin, Risk, Research and development, KRAS, Mutation, Therapy, TP53, Conference, SITC, Research, Investigational New Drug, Safety, Progression-free survival, Security (finance), Society, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ID, Intellectual property, Hlas, Development, Cash, State Administrative Expenses, NSCLC, Receptor, National Cancer Institute, Immunotherapy, Colorectal cancer, Food, Patient, Sleeping Beauty, Pharmaceutical industry, Vaccine

Third Quarter Ended September 30, 2022 Financial Results

Key Points: 
  • Third Quarter Ended September 30, 2022 Financial Results
    Collaboration Revenue: Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.
  • Research and Development Expenses: Research and development expenses were $7.9 million for the third quarter of 2022, compared to $14.5 million for the third quarter of 2021, a decrease of approximately 46%.
  • Cash and Cash Equivalents: As of September 30, 2022, Alaunos had approximately $37.8 million in cash and cash equivalents and restricted cash of $13.9 million.
  • Operating cash burn for the third quarter of 2022 was $6.1 million compared to $9.6 million in the third quarter of 2021, a decrease of $3.4 million or 36%.

Corner Therapeutics Debuts with Data Presentation on its Dendritic Cell Hyperactivation Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, FDA, Receptor, HDC, Immunity, TLR, Kagan, DC, B cell, Immunotherapy, Cytokine, Attention deficit hyperactivity disorder predominantly inattentive, Mouse, Therapy, Doctor of Philosophy, Cancer, Harvard Medical School, Infection, PD-1, SITC, Lymph, Disease, Neoplasm, Patient, CEO, Society, Antigen, FDA, Vaccine, Pharmaceutical industry, Corner

Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost memory T cell responses to disease, debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.

Key Points: 
  • Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost memory T cell responses to disease, debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.
  • Corner has developed a new therapeutic modalityDC hyperactivatorswhich induce the production of polyclonal populations of long-lived memory T cells that exhibit durable protective immunity to cancer.
  • Using proprietary chemicals and formulations, Corners DC hyperactivators mimic the molecular signals dendritic cells naturally experience during virulent infections.
  • The resulting hyperactive dendritic cells exhibit migratory capacity that is 30 times greater than what can be elicited by current FDA-approved immunostimulants.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Antibody, Safety, CDH17, Metastasis, CAR, Tight junction proteins, CLDN6, Drug discovery, Ligand, Industry, Trial of the century, Embryonic development, B-cell maturation antigen, Population, Glycoprotein, EC, BCMA, Cancer, Cell adhesion, B cell, Tissue, ROR1, Testicle, Receptor, Cadherin, Nephron, Probability, Patient, Cell, CD138, Skin, Competitive landscape, GPRC5D, Immunotherapy, Perspiration, Protein, Multiple myeloma, Organogenesis, CLDN9, Human, Adult, Dietary supplement, Vaccine, Retail, Medical imaging, Healthcare, Pharmaceutical industry, Risk management, Sales

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

ROR1-Targeted Therapy Research Report 2022: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Pharmaceutical, Health, Oncology, Embryonic development, SEC, Receptor, Cancer, Metastasis, Competitive landscape, Industry, Organogenesis, 2021 Essex County Council election, Publication, Safety, ROR1, Dietary supplement, Pharmaceutical industry, Vaccine, Medical imaging

The "ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field.
  • The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals.
  • Because of its tumor-specific expression and potential functional significance, ROR1 has become of interest as a target for various drug modalities, especially with enhanced effector function.

Taiwanese Bicycle Industry Growing at Fast Pace

Retrieved on: 
Thursday, July 14, 2022
Biking, Cycling, Retail, Sports, Other Retail, Giant, International trade, Conference, GPS, Multimedia, High Road, Future, TAITRA, Economy, Mio, USD, Receptor, Acer, Association, Industry, Ministry, Maxxis, Toronto Transit Commission fares

Gina Chang, Secretary General of the Taiwan Bicycle Association, provided an informative presentation on market developments as well as giving background on the entire Taiwan bicycle industry.

Key Points: 
  • Gina Chang, Secretary General of the Taiwan Bicycle Association, provided an informative presentation on market developments as well as giving background on the entire Taiwan bicycle industry.
  • In 2021, the exports of Taiwans bicycle industry exceeded 5 billion USD, which was a record high and illustrates how the industry is flourishing.
  • Moreover, the new mission is to become an even more valued partner by providing better services, explained the Secretary General of the Taiwan Bicycle Association.
  • Maxxis, the world-class tire company, introduced three top-quality bicycle tires at the event: High Road, Metropass and Receptor.

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors

Retrieved on: 
Tuesday, February 15, 2022
Biochemistry, Patient, MedImmune, Receptor, Board, Max Planck Institute of Biochemistry, Molecular biology, Leadership, Board of directors, GLOBE, Therapy, AstraZeneca, Doctor of Philosophy, Arrival (company), Cancer, Johns Hopkins University, Max Planck Society, Growth, Research, Helmy Eltoukhy, University, Santaris Pharma, Trustee, Drug development, Management, Pharmaceutical industry, Immunocore, Physiology

NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.

Key Points: 
  • NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment ofBahija Jallal, Ph.D.to its Board of Directors.
  • We are pleased to welcome an executive with Bahijas extensive senior leadership experience to our Board of Directors, saidBing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • Bahija is an internationally recognized biopharmaceutical leader, known for her entrepreneurial approach to discovering and delivering innovative biologics products to patients.
  • Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology.

Imvax Presents Data Showing Mechanisms for Broad Immune Activation by IGV-001

Retrieved on: 
Tuesday, November 9, 2021
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, CD4, PBMC, SITC, Disease, Immunotherapy, CD8, Society for Immunotherapy of Cancer, Society, Annual general meeting, Glioblastoma, Receptor, Vaccine, Pharmaceutical industry

Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today presented data showing the mechanisms by which IGV-001 produces broad immune activation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today presented data showing the mechanisms by which IGV-001 produces broad immune activation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • These exciting mechanistic data substantiate the anti-tumor effects weve observed in prior clinical trials of IGV-001.
  • It was then co-cultured with patient-derived peripheral blood mononuclear cells (PBMCs) to evaluate activated and memory T cell subsets and responses.
  • Imvaxs portfolio includes several programs designed to stimulate a patients immune system against the entire antigen signature of their tumor.